Horizon Kinetics Asset Management LLC Purchases 141 Shares of Eli Lilly and Company (NYSE:LLY)

Horizon Kinetics Asset Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 3.4% during the fourth quarter, Holdings Channel reports. The fund owned 4,257 shares of the company’s stock after acquiring an additional 141 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,286,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Kimelman & Baird LLC increased its stake in Eli Lilly and Company by 21.8% in the fourth quarter. Kimelman & Baird LLC now owns 44,562 shares of the company’s stock valued at $34,402,000 after acquiring an additional 7,972 shares during the last quarter. Cassady Schiller Wealth Management LLC increased its stake in Eli Lilly and Company by 10.1% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 458 shares of the company’s stock valued at $354,000 after acquiring an additional 42 shares during the last quarter. TCTC Holdings LLC increased its stake in Eli Lilly and Company by 2.3% in the fourth quarter. TCTC Holdings LLC now owns 2,727 shares of the company’s stock valued at $2,105,000 after acquiring an additional 62 shares during the last quarter. Pitti Group Wealth Management LLC increased its stake in Eli Lilly and Company by 3.0% in the fourth quarter. Pitti Group Wealth Management LLC now owns 1,708 shares of the company’s stock valued at $1,319,000 after acquiring an additional 49 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in Eli Lilly and Company by 11.1% in the fourth quarter. Parallel Advisors LLC now owns 26,277 shares of the company’s stock valued at $20,286,000 after acquiring an additional 2,628 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $813.55 on Monday. The company has a 50-day simple moving average of $830.81 and a two-hundred day simple moving average of $842.50. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market capitalization of $771.38 billion, a PE ratio of 69.47, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LLY shares. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Bank of America reaffirmed a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.